GMP, QMS Certification and On-site Inspection for Devices in Ethiopia

1. Key takeaways

Ethiopia writes Good Manufacturing Practice (GMP) compliance into the statutory conditions for registration: Article 20(4) of the Food and Drug Administration Proclamation No. 1112/2019 makes compliance with GMP by the manufacturer one of the preconditions under which a device may be registered. The routine way to satisfy this condition is submission of an ISO 13485 quality management system conformity certificate issued by an accredited conformity assessment body; for high-risk devices, the authority additionally requires a regulatory on-site inspection of the quality management system at the manufacturing facility. The system certificate and the on-site verification are two different layers — the former cannot replace the latter.

For planning purposes, this means two independent workstreams. The certificate workstream runs on the certification body’s audit calendar and must simply be kept current and site-accurate. The inspection workstream runs on the authority’s own scheduling, is fee-based, and its duration is not fixed in advance. Manufacturers of high-risk devices that build only the certificate lead time into their launch plans, and treat the on-site inspection as a formality, are the ones most often caught by schedule overruns at the final step before approval.

2. Legal basis

3. Expert insights

Insight 1: GMP is a statutory registration condition, not a bonus point. Article 20(4) places three conditions side by side: the manufacturer complies with good manufacturing practice; the dossier is assessed as satisfying safety, quality and effectiveness; and, where applicable, the laboratory quality testing requirements are satisfied. The three are cumulative requirements, and none can be missing. A technically excellent clinical file cannot compensate for an absent or lapsed GMP evidence, because the statute treats compliance as a threshold condition rather than a weighted factor in the overall assessment.

Insight 2: the QMS certificate and the GMP certificate are two separate entries in Chapter 1 of the dossier. Section 1.4 of EFDA/GDL/097 requires evidence of the quality management system (complete system), while Section 1.5 separately requires the good manufacturing practice (GMP) certificate (where applicable). Companies must prepare the two items separately when compiling the administrative dossier; they cannot be merged into a single submission. In practice this means maintaining both the ISO 13485 certificate and any GMP certificate as individually identifiable, individually valid documents, each traceable to the declared manufacturing site.

Insight 3: the trigger for on-site verification is tied to the risk class. According to the authority’s published practical estimate: Class III and IV devices require an on-site inspection of the manufacturing facility before registration; Class I and II devices and Class A and B IVDs are generally not audited on site before marketing; the exception concerns procedures that require assurance of sterility or measurement functions, where the relevant procedures may be audited before marketing; and the authority may also audit where it considers necessary (for example, in cases of frequent laboratory testing failures). The class label alone therefore never settles the audit question — the functional characteristics of the product do.

Insight 4: the product categories actually inspected on site are currently concentrated. According to the authority’s published practical estimate, although procedures are established, the authority currently conducts on-site inspections only for three device categories: condoms, medical gloves (including examination gloves) and rapid test kits. The selection rationale is the frequency of user complaints about post-market quality or performance failures, together with observations from the authority’s own laboratory. This shows that inspection resources are allocated on a risk-oriented basis — the program is small but pointed, and its scope can expand as complaint data accumulates.

Insight 5: on-site inspection fees are charged by the day and tied to product similarity and quantity. Regulation No. 370/2015 sets the service fee rates for GMP on-site inspection of pharmaceuticals and medical devices; in practice, the authority uses product similarity and quantity as the basis for the inspection service fee payable by the manufacturer, because these determine the number of inspection days required and the cost of the inspection team. The specific categories and amounts are listed in the formal letter issued by the authority. Budgeting should therefore treat the fee as variable until the letter arrives, and the letter itself should be retained as the payment record.

4. Practical recommendations

1. The ISO 13485 certificate must be issued by an accredited conformity assessment body and cover the declared manufacturing site.
2. List QMS and GMP evidence as separate items in the administrative dossier: never merge them.
3. Book on-site inspection slots early for Class III / IV devices: the scheduling cycle is uncertain.
4. Keep audit readiness for procedures related to sterility and measurement: even when the device class is low risk.
5. Treat condoms, medical gloves and rapid test kits as inspection-expected categories: complaints are frequent for these three.
6. Pay the inspection fee according to the amounts listed in the authority’s formal letter and retain the receipts.

5. Verification checklist

• □ ISO 13485 certificate covering the declared site obtained and within its validity period
• □ QMS and GMP evidence submitted as separate items in Chapter 1 of the dossier
• □ On-site inspection of the manufacturing facility booked or completed for high-risk devices
• □ Audit materials prepared for sterility- and measurement-related procedures
• □ On-site inspection service fee paid according to the authority’s formal letter
• □ All payment and inspection records retained

Regulatory information verified as of October 29, 2026. The statutory GMP condition, dossier entries and on-site verification arrangements described in this article follow Article 20(4) of Proclamation No. 1112/2019, EFDA/GDL/097 and the authority’s published practical estimate; when the inspection scope expands or fee rates change, the content must be re-verified.

• Ethiopia local resource: GRZAN supports manufacturers from the Chinese mainland and overseas in working with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA) applications, the institutional competency certificate (CoC) and import permit applications, including local agent scheme design and agency agreement review, SRA reliance route justification, UMDN coding and classification determination, technical dossier preparation, and vigilance and post-market surveillance system setup.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility determination, Essential Principles conformity justification, English-language labeling and instructions-for-use localization, vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn. For EFDA registration pathway and classification strategy support for the Ethiopian market, write to info@grzanglobal.com.